购物车
- 全部删除
- 您的购物车当前为空
AlbA-DCA, a conjugate of Albiziabioside A and a dichloroacetate acid subunit, markedly increases intracellular ROS, alleviates lactic acid accumulation in the tumor microenvironment, selectively kills cancer cells, and induces apoptosis.
AlbA-DCA, a conjugate of Albiziabioside A and a dichloroacetate acid subunit, markedly increases intracellular ROS, alleviates lactic acid accumulation in the tumor microenvironment, selectively kills cancer cells, and induces apoptosis.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100 mg | 询价 | 期货 | |
500 mg | 询价 | 期货 |
产品描述 | AlbA-DCA, a conjugate of Albiziabioside A and a dichloroacetate acid subunit, markedly increases intracellular ROS, alleviates lactic acid accumulation in the tumor microenvironment, selectively kills cancer cells, and induces apoptosis. |
体外活性 | AlbA-DCA exhibits cytotoxicity against MCF-7, HCT116, A375, 4T1, HBMEC, and LO2 cells (IC50s: 0.43 μM, 3.87 μM, 3.78 μM, 1.31 μM, 38.20 μM, and 53.14 μM, respectively). Treatment with AlbA-DCA (2 μM; 24 hours) induces apoptosis in MCF-7 cells, significantly up-regulating cytochrome c expression, down-regulating Bcl-2 expression, and enhancing caspase-9 expression. |
体内活性 | AlbA-DCA (2 mg/kg; subcutaneous injection; every 2 days; for 2 weeks; nude mice) demonstrates significant antitumor efficacy, nearly completely inhibiting tumor progression with no observed mortality or significant changes in body weight. Additionally, AlbA-DCA exhibits no apparent toxicity in the liver and kidney, nor any major abnormalities in the heart, liver, spleen, lung, and kidney. |
分子量 | 860.9 |
分子式 | C43H67Cl2NO12 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容